StockDuty ← Dashboard Nov 16, 2026 11:44 PM ET
SignalFDA/Bio

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TO

FDA Type C meeting success supports potential accelerated and full approval for IDE849 in neuroendocrine carcinomas.

What happened: IDEAYA Biosciences said a US FDA Type C meeting supported registrational trial designs for IDE849 in neuroendocrine carcinomas, including a single-arm cohort for potential accelerated approval and a randomized Phase 3 for full approval. Key numbers: Single-arm cohort about 90 refractory GEP-NEC patients; ORR 52.6% (10/19), median PFS 7.0 months, 9-month OS rate 82.4% in Why it matters: The company said the ESMO data support the clinical benefit of a DLL3-targeted ADC in NEC, and it aims to position IDE849 in a fast-evolving DLL3 landscape across refractory NEC and ES-SCLC. Market: -4.6% today ($30.36), -10.3% YTD, 0.6x vol — as of 22:47 UTC
IDEAYA Biosciences said a US FDA Type C meeting supported registrational trial designs for IDE849 in neuroendocrine carcinomas, including a single-arm cohort for potential accelerated approval and a randomized Phase 3 for full approval.
The company said the ESMO data support the clinical benefit of a DLL3-targeted ADC in NEC, and it aims to position IDE849 in a fast-evolving DLL3 landscape across refractory NEC and ES-SCLC. Market: -4.6% today ($30.36), -10.3% YTD, 0.6x vol — as of 22:47 UTC
Sources